High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Anagnostou, Valsamo K ^a   Lowery, Frank J ^a   Zolota, Vassiliki ^b   Tzelepi, Vassiliki ^b   Gopinath, Arun ^a   Liceaga, Camil ^a   Panagopoulos, Nikolaos ^b   Frangia, Konstantina ^c   Tanoue, Lynn ^a   Boffa, Daniel ^a   Gettinger, Scott ^a   Detterbeck, Frank ^a   Homer, Robert J ^a   Dougenis, Dimitrios ^b   Rimm, David L ^a   Syrigos, Konstantinos N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GIANT CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TUMOR CLASSIFICATION; VALIDATION PROCESS; ADENOCARCINOMA; CANCER STAGING; CELL DIFFERENTIATION; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; GREECE; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME; UNITED STATES; UPREGULATION;

ADENOCARCINOMA; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; COHORT STUDIES; CONNECTICUT; FEMALE; GREECE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77951941324     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-186     Document Type: Article

References (51)

1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348(6299):334-336. 10.1038/348334a0, 2250705.
2. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281(5381):1322-1326. 10.1126/science.281.5381.1322, 9735050.
3. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998, 281(5381):1305-1308. 10.1126/science.281.5381.1305, 9721089.
4. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends in cell biology 1998, 8(8):324-330. 10.1016/S0962-8924(98)01321-X, 9704409.
5. Kroemer G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ 1997, 4(6):443-456. 10.1038/sj.cdd.4400266, 16465265.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74(4):609-619. 10.1016/0092-8674(93)90509-O, 8358790.
7. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995, 13:513-543. 10.1146/annurev.iy.13.040195.002501, 7612233.
8. Choi J, Choi K, Benveniste EN, Rho SB, Hong YS, Lee JH, Kim J, Park K. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer research 2005, 65(13):5554-5560. 10.1158/0008-5472.CAN-04-4570, 15994927.
9. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 2004, 10(22):7662-7670. 10.1158/1078-0432.CCR-04-1036, 15569999.
10. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435(7042):677-681. 10.1038/nature03579, 15902208.
11. An J, Chervin AS, Nie A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007, 26(5):652-661. 10.1038/sj.onc.1209830, 16909121.
12. Skommer J, Wlodkowic D, Matto M, Eray M, Pelkonen J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leukemia research 2006, 30(3):322-331. 10.1016/j.leukres.2005.08.022, 16213584.
13. Cory S, Harris AW, Strasser A. Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells. Philos Trans R Soc Lond B Biol Sci 1994, 345(1313):289-295. 10.1098/rstb.1994.0108, 7846127.
14. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008, 26(6):870-876. 10.1200/JCO.2007.14.3461, 18281659.
15. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer research 2007, 67(3):1176-1183. 10.1158/0008-5472.CAN-06-2203, 17283153.
16. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer cell 2006, 10(5):389-399. 10.1016/j.ccr.2006.08.027, 17097561.
17. Wong WW, Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB life 2008, 60(6):390-397. 10.1002/iub.51, 18425793.
18. Zeitlin BD, Zeitlin IJ, Nor JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008, 26(25):4180-4188. 10.1200/JCO.2007.15.7693, 2654265,2654265, 18757333.
19. Fokkema E, Timens W, de Vries EG, de Jong S, Fidler V, Meijer C, Groen HJ. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung cancer (Amsterdam, Netherlands) 2006, 52(2):241-247.
20. Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung cancer (Amsterdam, Netherlands) 2009,
21. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, et al. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori 2008, 94(3):398-405.
22. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. British journal of cancer 2003, 89(1):55-64. 10.1038/sj.bjc.6601095, 2394216, 12838300.
23. Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, Laskin J. BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer. J Thorac Oncol 2009,
24. Shibata Y, Hidaka S, Tagawa Y, Nagayasu T. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer research 2004, 24(3b):1925-1928.
25. Silvestrini R, Costa A, Lequaglie C, Mochen C, Veneroni S, Leutner M, Ravasi G. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch 1998, 432(5):441-444. 10.1007/s004280050188, 9645443.
26. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol 2003, 29(8):654-657. 10.1016/S0748-7983(03)00138-0, 14511612.
27. Ulukus EC, Kargi HA, Sis B, Lebe B, Oztop I, Akkoclu A, Onen A, Sanli A. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Immunohistochem Mol Morphol 2007, 15(1):31-37. 10.1097/01.pai.0000201808.35931.78, 17536304.
28. Yaren A, Oztop I, Kargi A, Ulukus C, Onen A, Sanli A, Binicier O, Yilmaz U, Alakavuklar M. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. International journal of clinical practice 2006, 60(6):675-682. 10.1111/j.1368-5031.2006.00742.x, 16805752.
29. Gregorc V, Darwish S, Ludovini V, Pistola L, De Angelis V, Mihaylova Z, Bellezza G, Sidoni A, Cavaliere A, Bucciarelli E, et al. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2003, 42(3):275-281.
30. Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Human pathology 2002, 33(1):105-110. 10.1053/hupa.2002.30183, 11823980.
31. Ritter JH, Dresler CM, Wick MR. Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Human pathology 1995, 26(11):1227-1232. 10.1016/0046-8177(95)90198-1, 7590697.
32. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC, Betticher DC. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. British journal of cancer 1999, 79(5-6):952-958. 10.1038/sj.bjc.6690152, 2362678, 10070896.
33. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC, Baldi A, et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 2004, 44(1):54-63. 10.1111/j.1365-2559.2004.01750.x, 14717670.
34. Hwang JH, Lim SC, Kim YC, Park KO, Ahn SJ, Chung WK. Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. International journal of radiation oncology, biology, physics 2001, 50(1):13-18.
35. Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands) 1998, 22(3):181-190.
36. Poleri C, Morero JL, Nieva B, Vazquez MF, Rodriguez C, de Titto E, Rosenberg M. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest 2003, 123(6):1858-1867. 10.1378/chest.123.6.1858, 12796161.
37. Travis WDBE, Muller-Hermelink HK, Harris CC. WHO classification of tumors of the lung, pleura and mediastinum. 2004, Lyon: IARC Press.
38. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. Journal of the National Cancer Institute 2005, 97(24):1808-1815.
39. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature medicine 2002, 8(11):1323-1327. 10.1038/nm791, 12389040.
40. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10(21):7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
41. de Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer research 1994, 54(1):256-260.
42. Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008, 10(2):R35. 10.1186/bcr1998, 2397537, 18430249.
43. Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer 2003, 98(1):135-143. 10.1002/cncr.11461, 12833466.
44. Zhang J, Kamdar O, Le W, Rosen GD, Upadhyay D. Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. American journal of respiratory cell and molecular biology 2009, 40(2):135-146. 10.1165/rcmb.2007-0277OC, 2633138, 18676776.
45. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(18):9545-9552. 10.1073/pnas.93.18.9545, 38465, 8790367.
46. Cheng WC, Berman SB, Ivanovska I, Jonas EA, Lee SJ, Chen Y, Kaczmarek LK, Pineda F, Hardwick JM. Mitochondrial factors with dual roles in death and survival. Oncogene 2006, 25(34):4697-4705. 10.1038/sj.onc.1209596, 16892083.
47. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science (New York, NY) 1997, 278(5345):1966-1968.
48. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003, 362(9382):433-439. 10.1016/S0140-6736(03)14068-8, 12927430.
49. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England journal of medicine 2006, 355(24):2542-2550. 10.1056/NEJMoa061884, 17167137.
50. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):277S-289S. 10.1378/chest.07-1381, 17873174.
51. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20(21):4285-4291. 10.1200/JCO.2002.02.068, 12409326.